Characteristics | HSV N = 7 | EV N = 103 | P-Valuea | |
---|---|---|---|---|
Demographic | Male gender, n (%) | 3 (43) | 54 (52) | 0.71 |
Age at onset (d), median (IQR) | 14 (6–19) | 25 (12–33) | 0.02 | |
Overall | 16 (6–19) | 10 (6–27) | 1.0 | |
Subset fulfilling meningoencephalitis criteria [Proportion (%) age < 28d] | [6/6 (100)] | [6/7 (86)] | 1.0 | |
Gestation (wks), median (IQR) | 37 (37–38) | 37 (29–38) | 0.31 | |
Clinical | ICU admission, n (%) | 4 (57) | 12/98 (12) | 0.010 |
Seizures, n (%) | ||||
Had at least one seizure at any time | 4 (57) | 5 (5) | .001 | |
Had a seizure in first 72 h of admission | 2 (29) | 3 (3) | 0.03 | |
Had at least one seizure during the admission | 3 (43) | 5 (5) | 0.008 | |
Had seizures only after discharge | 1 (16) | 0 (0) | 0.06 | |
Multisystemic infectionb | 5 (71) | 8 (8) | < 0.001 | |
Coinfection with bacteria or fungus, n (%) | 1 (14) | 4 (4) | 0.28 | |
Imaging | Abnormal head imagingc, n (%) | 4/7 (57) | 5/26 (19) | 0.068 |
Meningoencephalitis, n (%) | 6/7 (86) | 7 (7) | < 0.001 | |
Hospital stay | Length of stay (d), median (IQR) | 25 (21–43) | 3 (3–5) | < 0.001 |
Follow-up | Follow-up (mo), median (IQR) | 16 (10–24) | 6 (1–12) | 0.03 |
Neurodevelopmental or neurological sequelae | Neurodevelopmental abnormalities at discharge or follow-upd, n (%) | 3/6 (50) | 7/102 (7) | 0.01 |
Outcomes | Death or neurological complicationse or neurodevelopmental abnormalities, n (%) | |||
All infants | 4/7 (57) | 8 (8) | 0.002 | |
Infants with encephalitis | 4/6 (67) | 4/7 (57) | 1.00 |